氢吗啡酮
外观
此條目可参照英語維基百科相應條目来扩充。 (2024年3月1日) |
臨床資料 | |
---|---|
商品名 | Dilaudid, Palladone, others |
其他名稱 | Dihydromorphinone |
AHFS/Drugs.com | Monograph |
MedlinePlus | a682013 |
核准狀況 | |
懷孕分級 | |
依賴性 | High[2] |
成癮性 | High[3] |
给药途径 | By mouth, intramuscular, intravenous, subcutaneous |
藥物類別 | Opioid |
ATC碼 | |
法律規範狀態 | |
法律規範 |
|
藥物動力學數據 | |
生物利用度 | By mouth: 30–35%, Intranasal: 52–58%,[4] IV/IM: 100% |
血漿蛋白結合率 | 20% |
药物代谢 | 肝 |
藥效起始時間 | 15-30分钟[5] |
生物半衰期 | 2–3 hours[6] |
作用時間 | 4 to 5 hrs[5] |
排泄途徑 | Kidney |
识别信息 | |
| |
CAS号 | 466-99-9 |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.006.713 |
化学信息 | |
化学式 | C17H19NO3 |
摩尔质量 | 285.34 g·mol−1 |
3D模型(JSmol) | |
水溶性 | HCl salt: 333 |
| |
|
氢吗啡酮(英語:hydromorphone,也称为二氢吗啡酮,dihydromorphinone,商品名:Dilaudid)是一种含氮有机化合物,化学式C17H19NO3,是一种用于缓解中度至重度疼痛的吗啡喃類阿片药物[5]。
参考文献
[编辑]- ^ Hydromorphone Use During Pregnancy. Drugs.com. 19 November 2019 [16 May 2020]. (原始内容存档于2020-11-26).
- ^ Bonewit-West K, Hunt SA, Applegate E. Today's Medical Assistant: Clinical and Administrative Procedures. Elsevier Health Sciences. 2012: 571 [2024-02-12]. ISBN 9781455701506. (原始内容存档于2023-01-10) (英语).
- ^ Bonewit-West K, Hunt SA, Applegate E. Today's Medical Assistant: Clinical and Administrative Procedures. Elsevier Health Sciences. 2012: 571 [20 August 2019]. ISBN 9781455701506. (原始内容存档于10 January 2023).
- ^ Coda BA, Rudy AC, Archer SM, Wermeling DP. Pharmacokinetics and bioavailability of single-dose intranasal hydromorphone hydrochloride in healthy volunteers. Anesthesia and Analgesia. July 2003, 97 (1): 117–23, table of contents. CiteSeerX 10.1.1.551.6509 . PMID 12818953. S2CID 22694749. doi:10.1213/01.ANE.0000066311.40978.4F.
- ^ 5.0 5.1 5.2 Hydromorphone Hydrochloride Monograph for Professionals. Drugs.com. American Society of Health-System Pharmacists. [15 April 2019]. (原始内容存档于2019-06-01) (英语).
- ^ Vallner JJ, Stewart JT, Kotzan JA, Kirsten EB, Honigberg IL. Pharmacokinetics and bioavailability of hydromorphone following intravenous and oral administration to human subjects. Journal of Clinical Pharmacology. April 1981, 21 (4): 152–156. PMID 6165742. S2CID 29864565. doi:10.1002/j.1552-4604.1981.tb05693.x.
- ^ Anvisa. RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control]. Diário Oficial da União. 31 March 2023 (4 April 2023) [16 August 2023]. (原始内容存档于3 August 2023) (巴西葡萄牙语).
外部链接
[编辑]- Article discussing withdrawal of extended-release hydromorphone from the U.S. market (页面存档备份,存于互联网档案馆)
- Dihydromorphinones from morphine & analogues (页面存档备份,存于互联网档案馆)
- United States DEA's perspective, including statistics on manufacture and prescription levels from 1998 to 2006
- "When is a pain doctor a drug pusher?" (页面存档备份,存于互联网档案馆), The New York Times, 17 June 2007